GPT Healthcare Limited reported a standalone net profit of ₹12.7 crore for the first quarter ended June 30, 2026, marking a 65.7% year-on-year increase from ₹7.7 crore in Q1FY26. The surge was driven by robust margin expansion, with EBITDA margins widening to 19.16% from 16.21%, and revenue growth of 17.8% to ₹1.26b Rupees. This performance underscores the company's ability to generate higher operating leverage despite rising input costs, supported by improved clinical mix and patient volumes across its network.

The Board of Directors approved the unaudited standalone financial results during a meeting held on August 3, 2026, in Kolkata. Subsequently, the company participated in an earnings conference call on August 4, 2026, at 11:00 AM (IST) to discuss these results with investors. Statutory auditors S.R. Batliboi & Co. LLP issued an unmodified limited review conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

The following table summarises the key standalone financial metrics for the quarter:

Earnings per share (basic and diluted) stood at ₹1.55 for the quarter, compared to ₹0.94 in Q1FY26. The company maintained its net-debt-free position, supporting sustainable returns through disciplined capital allocation. No unpublished price-sensitive information was shared during the conference call.

Operational Updates and Hospital Performance

Operational performance remained healthy, with Average Rate Per Occupied Bed (ARPOB) increasing to ₹42,350, driven by an improved clinical mix. Network occupancy stood at 58.07% overall for mature hospitals, excluding the newly commissioned Raipur facility. Including Raipur, the overall network occupancy was 45.5%. Mature hospitals continued to deliver resilient performance:

• ILS Salt Lake: Strengthened leadership in robotic-assisted surgery with over 800 cumulative procedures.
• ILS Dum Dum: Remained the highest-occupied hospital in the network, supported by its established renal transplant programme with more than 700 transplants completed. Management expects Dum Dum to reach optimum occupancy levels this year, with 70% occupancy becoming normal by Q3.
• ILS Agartala: Expanded its oncology platform with PET Scan and Linear Accelerator facilities, completing over 700 radiation therapy procedures. Management is confident that the Agartala hospital is on track to meet its original year-end occupancy target.
• ILS Howrah: Launched MAKO robotic knee replacement surgeries, supporting higher realisations.
• ILS Raipur: Commenced operations in May 2025, ramping up high-acuity specialties including oncology, cardiology, and transplant services. It received its liver transplant license.

Management Guidance and Outlook

Management shared detailed forward-looking guidance during the earnings concall. The key targets and projections are summarised below:

For the Raipur hospital, management expects to close the year at around 30% occupancy and anticipates achieving operational breakeven around the 20-month mark. The Jamshedpur hospital is expected to be commissioned in late Q4 FY27, with an initial ARPOB projected at ₹38,000–40,000 and an anticipated breakeven in approximately 24 months. The company also plans to expand its network capacity to over 1,000 beds within the next two years by evaluating opportunities for a seventh hospital.

On ARPOB growth, management noted that increases are assumed to be driven primarily by an improved specialty and case mix, which contributes 50-60% of the increase, rather than the smaller contribution from inflation-linked annual tariff revisions in October. Additionally, international patient inflows are expected to return to pre-disruption levels within the next six months, aided by policy changes requiring targeted hospital names for visa requests.

What the Numbers Show

The divergence between revenue growth and net profit growth of 65.7% highlights strong margin expansion, further reinforced by the EBITDA margin widening to 19.16% from 16.21% year-on-year. While key input costs such as materials and labor increased, they did so at a rate lower than revenue generation. This efficiency is particularly notable given the company's focus on a single reportable segment—healthcare services in India—suggesting effective pricing power or volume optimization in its service delivery model. Management's guidance of approximately 21% EBITDA margins for FY27, translating to an annual EBITDA of ₹110–115 crore, reflects confidence in sustaining this operational momentum, with long-term ROCE and ROE targets of approximately 25% anchoring the company's capital allocation strategy.

GPT Healthcare Limited will host an earnings call on August 4, 2026, to discuss its un-audited financial results for the first quarter ended June 30, 2026. The conference, scheduled for 11:00 AM IST, provides investors and analysts with an opportunity to review the company's performance in Q1FY27. This disclosure is made in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The event will be conducted via a conference bridge, allowing participation from both domestic and international stakeholders. Pre-registration is advised to avoid wait times during the session. The company has provided multiple dial-in options to facilitate global access.

Conference Details

The earnings call will feature senior management discussing the financial outcomes of the quarter. Below are the key logistical details for the event:

Management Participants

The following executives will participate in the discussion:

• Atul Tantia, Group CFO
• Anurag Tantia, Executive Director
• Kriti Tantia, CFO

The notice was issued by Ankur Sharma, Company Secretary and Compliance Officer, on July 25, 2026. Investors interested in attending are requested to pre-register through the provided link to ensure smooth access to the conference line.